Literature DB >> 24615774

Sorafenib inhibits ABCG2 and overcomes irinotecan resistance--letter.

Malcolm A Smith1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24615774      PMCID： PMC4006365          DOI： 10.1158/1535-7163.MCT-13-0968

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN： 1535-7163            Impact factor:   6.261


× No keyword cloud information.
  3 in total

1.  Plasma protein binding of sorafenib, a multi kinase inhibitor: in vitro and in cancer patients.

Authors:  Maria Cristina Villarroel; Keith W Pratz; Linping Xu; John J Wright; B Douglas Smith; Michelle A Rudek
Journal:  Invest New Drugs       Date:  2011-11-17       Impact factor: 3.850

2.  FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML.

Authors:  Keith W Pratz; Takashi Sato; Kathleen M Murphy; Adam Stine; Trivikram Rajkhowa; Mark Levis
Journal:  Blood       Date:  2009-12-10       Impact factor: 22.113

3.  Sorafenib overcomes irinotecan resistance in colorectal cancer by inhibiting the ABCG2 drug-efflux pump.

Authors:  Thibault Mazard; Annick Causse; Joelle Simony; Wilhem Leconet; Nadia Vezzio-Vie; Adeline Torro; Marta Jarlier; Alexandre Evrard; Maguy Del Rio; Eric Assenat; Pierre Martineau; Marc Ychou; Bruno Robert; Celine Gongora
Journal:  Mol Cancer Ther       Date:  2013-08-19       Impact factor: 6.261
  3 in total
  1 in total

1.  Selective and Irreversible Induction of Necroptotic Cell Death in Lung Tumorspheres by Short-Term Exposure to Verapamil in Combination with Sorafenib.

Authors:  Juan Sebastian Yakisich; Yogesh Kulkarni; Neelam Azad; Anand Krishnan V Iyer
Journal:  Stem Cells Int       Date:  2017-10-19       Impact factor: 5.443
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.